skip to content

New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.